Sector News

Novo Nordisk to invest $2.3bn to expand Danish manufacturing facilities

June 16, 2023
Life sciences

Novo Nordisk has unveiled plans to make a DKr15.9bn ($2.29bn) investment, starting from 2023, to expand its manufacturing facilities in Hillerød, Denmark.

The new investment will create additional production capacity, increase the company’s capacity to meet future demand and enable the development of its future clinical late-phase product portfolio.

The investment will be used for expanding its existing Danish active pharmaceutical ingredient (API) production facility to progress its future serious and chronic disease portfolio.

The funding will also be used to construct a new 65,000m² multi-product manufacturing facility, designed with maximum flexibility to accommodate new processes and featuring an advanced working environment and technology.

The new facility will be future-proof and cost-effective, with a focus on optimal and compact process flows to reduce water and energy consumption.

Construction has already commenced, with API production expected to begin by early 2029.

The expansion project is anticipated to create 340 new jobs.

Novo Nordisk Product Supply, Quality and IT executive vice-president Henrik Wulff stated: “This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide.

“The investment announced today confirms Hillerød and Denmark as cornerstones in our global footprint, and I would like to take this opportunity to thank the Danish government and parliament for their continued focus on ensuring good and stable infrastructure and supplies, allowing us to continue to expand our production capacity to the benefit of patients living with serious chronic diseases.”

Source: pharmaceutical-technology.com

comments closed

Related News

June 22, 2024

Ferring launches online assessment tool, educational platform around male fertility

Life sciences

Because infertility is often branded largely as a women’s issue, many men may be unaware of their own possible role in the matter and may not undergo testing in a timely manner—even though research has shown that men “substantially” contribute to about half of all cases of infertility.

June 22, 2024

Johnson & Johnson blueprints €125M plant upgrade as part of 5-year Italy investment

Life sciences

After plugging nearly 50 million euros into its Italy R&D in the first half of the decade, Johnson & Johnson Innovative Medicine is significantly upping its commitment to the country. Over the next five years, J&J Innovative Medicine, which recently rebranded from Janssen, will plug a projected 580 million euros ($621.7 million) into its Italian business, the company said in a press release.

June 22, 2024

India’s Lupin announces CEO pick for new subsidiary as it moves into the CDMO arena

Life sciences

From vitamin maker to pharmaceutical specialist and now contract manufacturer, India’s Lupin is embarking on a new phase of its corporate journey. Lupin on Monday unveiled its new subsidiary, Lupin Manufacturing Solutions, which is poised to work on the development, production and sale of active pharmaceutical ingredients.

How can we help you?

We're easy to reach